Despite the success of the roll-out of antiretroviral therapy (ART) in sub-Saharan Africa, not all patients prescribed ART have their health fully restored. For example, one of the most common cancers in the pre- ART era Kaposi's sarcoma (KS) continues to be amongst the most frequent even after ART. Surprisingly, there has been no prospective account of KS that develops after start of ART. Thus, the specific aims of Research Project 3 of the Uganda-UCSF Consortium are to:
Aim 1 : Describe the clinical and labor3tory ch3r3cteristics of p3tients who develop KS despite being prescribed ART. We will determine, in addition to routine characteristics available in existing data sources (e.g., sex and age), a more comprehensive and germane set of clinical and laboratory characteristics heretofore not systematically recorded at the immediate time of KS diagnosis after start of ART.
Aim 2 : Evaluate determinants of incident KS despite ART-mediated virologic suppression. Among individuals with virologic suppression (i.e., undetectable plasma HIV RNA), we will evaluate several biological mechanisms for KS development. Specifically, we will assess, with several biomarkers, the roles of CD4+ lymphopenia, systemic inflammation, and immunosenescence in the development of KS.
Aim 3 : Determine survival after KS occurrence 3mong p3tients prescribed ART 3nd compare this to survival of KS that occurs prior to ART and to patients without KS. Because we expect most patients who develop KS after ART initiation to have early clinical stage of disease, we hypothesize that survival will be better than patients diagnosed with KS pre-ART. However, we hypothesize that survival among those diagnosed with KS after ART will be worse than comparable patients without KS who are on ART. To address these aims, the Consortium will take advantage of its collaboration with East Africa IeDEA, one of the only networks large enough to prospectively study cancer in Africa. Through the established KS biopsy services in IeDEA, we will characterize KS diagnoses through rapid case ascertainment. We will also use the well-enumerated population to perform a nested case-control study of the determinants of KS. We expect this work to become a resource to understand the pathogenesis of KS in the ART era, setting the stage for new interventions above and beyond ART to further reduce KS risk.

Public Health Relevance

Even with the new therapy for HIV infection, the cancer known as Kaposi's sarcoma continues to occur. This is true in resource-rich settings like the U.S, and particularly true in resource-limited settings like sub- Saharan Africa. This research project will investigate which types of patients develop Kaposi's sarcoma despite being prescribed ART, why this occurs, and how long such patients live after being diagnosed.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54CA190153-01
Application #
8933032
Study Section
Special Emphasis Panel (ZCA1-RPRB-O (M2))
Program Officer
Dominguez, Geraldina
Project Start
2014-09-17
Project End
2019-08-31
Budget Start
2014-09-17
Budget End
2015-08-31
Support Year
1
Fiscal Year
2014
Total Cost
$86,488
Indirect Cost
$13,716
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Amerson, Erin; Woodruff, Carina Martin; Forrestel, Amy et al. (2016) Accuracy of Clinical Suspicion and Pathologic Diagnosis of Kaposi Sarcoma in East Africa. J Acquir Immune Defic Syndr 71:295-301
Nakalembe, Miriam; Mutyaba, Twaha; Mirembe, Florence (2016) Acceptability of study procedures (self-collected introital swabs, blood draws and stool sample collection) by students 10-16 years for an HPV vaccine effectiveness study: a pilot study. BMC Res Notes 9:170
Semeere, Aggrey; Wenger, Megan; Busakhala, Naftali et al. (2016) A prospective ascertainment of cancer incidence in sub-Saharan Africa: The case of Kaposi sarcoma. Cancer Med 5:914-28
Huchko, Megan J; Maloba, May; Nakalembe, Miriam et al. (2015) The time has come to make cervical cancer prevention an essential part of comprehensive sexual and reproductive health services for HIV-positive women in low-income countries. J Int AIDS Soc 18:20282
Freeman, Esther; Semeere, Aggrey; Wenger, Megan et al. (2015) Pitfalls of practicing cancer epidemiology in resource-limited settings: the case of survival and loss to follow-up after a diagnosis of Kaposi's sarcoma in five countries across sub-Saharan Africa. BMC Cancer 16:65
Tjiam, M Christian; Taylor, James P A; Morshidi, Mazmah A et al. (2015) Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification. J Immunol 194:5320-8
Laker-Oketta, Miriam O; Wenger, Megan; Semeere, Aggrey et al. (2015) Task Shifting and Skin Punch for the Histologic Diagnosis of Kaposi's Sarcoma in Sub-Saharan Africa: A Public Health Solution to a Public Health Problem. Oncology 89:60-5
Forrestel, A K; Naujokas, A; Martin, J N et al. (2015) Bacillary angiomatosis masquerading as Kaposi's sarcoma in East Africa. J Int Assoc Provid AIDS Care 14:21-5
McKnight, Tracy R; Yoshihara, Hikari A I; Sitole, Lungile J et al. (2014) A combined chemometric and quantitative NMR analysis of HIV/AIDS serum discloses metabolic alterations associated with disease status. Mol Biosyst 10:2889-97